FDMT
4D Molecular Therapeutics Inc
About FDMT
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company. The Company is focused on creating and developing targeted and evolved adeno-associated viruses (AAV) vectors. The Company’s product candidates are focused various areas, including ophthalmology, cardiology, and pulmonology. The Company's product candidates include 4D-125, 4D-150, 4D-110, 4D-310, and 4D-710. 4D-125 for the treatment of patients with X-Linked Retinitis Pigmentosa (XLRP) with retinitis pigmentosa GTPase regulator (RPGR) gene. 4D-150 is developed for the treatment of wet age-related macular degeneration (wet-AMD). 4D-110 is developed for the treatment of choroideremia. 4D-310 is developed for the systemic treatment of Fabry disease. The Company is developing 4D-710 for the treatment of a broad range of patients with cystic fibrosis independent of their cystic fibrosis transmembrane conductance regulator (CFTR).
Buy US stocks in Australia starting with FDMT. Open an account and start investing today!
$742.43M
-
0.00%
192.83K
$22.61
$21.52
$22.61
$26.49
$5.32
FDMT FAQs
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in FDMT
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.